HIV-1
Conditions
Keywords
HIV-1, Child, Adolescent, Growth, Lipodystrophy, ARV treatment, Senegal
Brief summary
The advent of highly active antiretroviral treatment has resulted in the survival into adolescence of an increasing proportion of infants and children with perinatal HIV infection in Senegal. However, the transformation of HIV into a chronic disease needing lifelong antiretroviral treatment (ART) raises new challenges, among others related to a disturbance of glucose metabolism, lipid abnormalities, in addition to the potential effects on children's growth and puberty. Little is known on nutritional and metabolic changes in HIV-infected children on ART in Africa, while implementation of the latest WHO recommendations should eventually lead to an increase in the number of children on ART in this region. Moreover, bio-clinical evolution of untreated children is poorly documented in the African context. It therefore urgently needed to institute a cohort study to evaluate, in the long term, the impact of HIV infection and/or ART on nutritional and metabolic disorders and to characterize the risk factors of their occurrence in children and adolescents infected as they move through adolescent into adulthood.
Interventions
None listed
Sponsors
ANRS, Emerging Infectious Diseases
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
2 Years to 15 Years
Healthy volunteers
No
Inclusion criteria
* HIV-1 infection * Age equal or above 2 years and bellow 16 years * Follow-up in the participating site * Informed consent signed by at least on of the parents or legal guardian who is aware of the child's HIV status
Exclusion criteria
* HIV-2 or HIV-1+2 infection * children represented by a legal guardian who is not informed about the child's HIV status * Unable to comply with study requirements or procedures according to the investigator's opinion
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of blood lipid and glucose abnormalities | Annually for 3 years from the anniversary date of the study | Repeated measurement of blood glucose, total cholesterol, HDL, LDL and triglycerides |
| Prevalence of delayed growth | Baseline | Delayed growth is defined by height for age \< -2 z-scores, wasting (%) by weight-for height \< -2 z-scores and/or BMI-age \< -2 z-scores |
| Prevalence of delayed puberty | Baseline | Delayed puberty is assessed by age of entry into puberty and the age of transition to different Tanner staging |
| Prevalence of lipodystrophy | Baseline | Lipodystrophy (lipoatrophy, lipohypertrophy, combined forms) is defined by direct observation and by joint analysis of anthropometric measures associated with fat tissue index and lean tissue index measured by electrical bio-impedancemetry |
| Prevalence of blood lipids ans glucose abnormalities | Baseline | Measurement of blood glucose, total cholesterol, HDL, LDL and triglycerides |
| Incidence of delayed growth | Annually for 3 years from the anniversary date of the study | Delayed growth is defined by height for age \< -2 z-scores, wasting (%) by weight-for height \< -2 z-scores and/or BMI-age \< -2 z-scores |
| Incidence of delayed puberty | Annually for 3 years from the anniversary date of the study | Assessed by age of entry into puberty and the age of transition to a different Tanner stage |
| Incidence of lipodystrophy | Annually for 3 years from the anniversary date of the study | defined by direct observation and by joint analysis of anthropometric measures associated with changes in fat tissue index and lean tissue index measured by electrical bio-impedancemetry |
Countries
Senegal
Outcome results
None listed